

## 英文論文

- 1.Kawarabayashi T, Nishikimi T, Takeuchi K, Takeda T Pseudo-coarctation of the abdominal aorta associated with renovascular hypertension. *Angiology* 1985;36:215-8
- 2.Nishikimi T, Kohno M, Matsuura T, Akioka K, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T Effect of exercise on circulating atrial natriuretic polypeptide in valvular heart disease. *Am J Cardiol* 1986 ;58:1119-20
- 3.Nishikimi T, Kohno M, Matsuura T, Kanayama Y, Akioka K, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T Circulating atrial natriuretic polypeptide during exercise in patients with essential hypertension. *J Hypertens Suppl* 1986 ;4:S546-9
- 4.Kiriike N, Maeda Y, Nishiwaki S, Izumiya Y, Katahara S, Mui K, Kawakita Y, Nishikimi T, Takeuchi K, Takeda T Iatrogenic torsade de pointes induced by thioridazine. *Biol Psychiatry* 1987 ;22:99-103
- 5.Yasuda M, Nishikimi T, Murai K, Oku H, Takeuchi K, Takeda T, Komatsu H Cardiac function of patients with essential hypertension during exercise and isoproterenol infusion. *Jpn Circ J* 1987 ;51:125-37
- 6.Nishikimi T, Ochi H, Hirota K, Ikuno Y, Oku H, Takeuchi K, Takeda T Primary pericardial mesothelioma detected by gallium-67 scintigraphy. *J Nucl Med* 1987 ;28:1210-2
- 7.Nishikimi T, Oku H, Hirota K, Murai K, Kawarabayashi T, Yoshiyama M, Akioka K, Teragaki M, Yasuda M, Takenuchi K, Takeda T. Right and left coronary artery to left ventricle fistula detected by color Doppler flow mapping. *Am Heart J* 1987 ;114:890-4
- 8.Akioka A, Kohno M, Nishikimi T, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T. Influence of nisoldipine on hemodynamics and atrial natriuretic polypeptide at exercise loading in hypertensive patients : Nisoldipine edited by P.G.Hughenoltz, J.Meyer, Springer-Vulag Berlin Heiderberg 1987 ;159-164
- 9.Nishikimi T, Kohno M, Itagane H, Hirota K, Akioka K, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T Influence of exercise on plasma atrial natriuretic factor levels in patients with

myocardial infarction. *Am Heart J* 1988 ;115:753-60

10. Yasuda M, Nishikimi T, Akioka K, Teragaki M, Oku H, Takeuchi K, Takeda T, Naka K, Okuda K, Ikuno Y Relationship between cardiac function and the sympathetic nervous system during exercise in patients with essential hypertension. *Jpn Circ J* 1988 ;52:1121-31

11. Kohno M, Yasunari K, Murakawa K, Yokokawa K, Akioka K, Teragaki M, Yasuda M, Nishikimi T, Oku H, Takeuchi K, Takeda T. Physiological significance of atrial natriuretic peptides in essential hypertension. *Jpn Circ J* 1988 ;52:1465-7

12. Murai K, Hirota K, Nishikimi T, Kawarabayashi T, Yoshiyama M, Yasuda M, Teragaki M, Akioka K, Oku H, Takeuchi K, Takeda T. Pheochromocytoma with electrocardiographic change mimicking angina pectoris and cyclic change in direct arterial pressure—a case report: *Angiology* 1991;42:157-161

13. Uchino K, Frohlich ED, Nishikimi T, Isshiki T, Kardon MB Spontaneously hypertensive rats demonstrate increased renal vascular alpha 1-adrenergic receptor responsiveness. *Am J Physiol* 1991 ;260:R889-93

14. Uchino K, Nishikimi T, Frohlich ED Alpha 1-adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR. *Am J Physiol* 1991 ;261:R576-80

15. Nishikimi T, Uchino K, Frohlich ED Effects of alpha 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats. *Am J Physiol* 1992 ;262:R198-203

16. Isshiki T, Nishikimi T, Uchino K, Kardon MB, Frohlich ED Diltiazem reduces glomerular pressure in spontaneously hypertensive rats. *Cardiovasc Drugs Ther* 1992 ;6:91-2

17. Uchino K, Nishikimi T, Frohlich ED. The role of circulating and therapeutic agents on the intrarenal circulation. *Current Opinion Cardiology* 1992,7:752-758

18. Nishikimi T, Frohlich ED Glomerular hemodynamics in aortocaval fistula rats: role of renin-angiotensin system. *Am J Physiol* 1993 ;264:R681-6

19. Omura T, Teragaki M, Tani T, Yamagishi H, Yanagi S, Nishikimi T, Yoshiyama M, Toda I, Akioka K, Takeuchi K, Takeda T. Estimation of infarct size using serum troponin T concentration in patients with acute myocardial infarction. *Jpn Circ J* 1993 ;57:1062-70
20. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. *J Mol Cell Cardiol* 1993 ;25:1369-80
21. Yoshiyama M, Miura K, Nishikimi T, Teragaki M, Todi I, Akioka K, Takeuchi K, Takeda T. Role of nitric oxide in the vasodilatory responses to acetylcholine and bradykinin in perfused hearts. *Jpn Circ J* 1993 ;57:1159-63
22. Nishikimi T, Miura K, Minamino N, Takeuchi K, Takeda T. Role of endogenous atrial natriuretic peptide on systemic and renal hemodynamics in heart failure rats. *Am J Physiol* 1994 ;267:H182-6
23. Nishikimi T, Kitamura K, Saito Y, Shimada K, Ishimitsu T, Takamiya M, Kangawa K, Matsuo H, Eto T, Omae T, Matsuoka H. Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. *Hypertension* 1994 ;24:600-4
24. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. *J Clin Invest* 1994 ;94:2158-61
25. Numabe A, Nishikimi T, Komatsu K, Frohlich ED. Intrarenal hemodynamics in low- and high-output cardiac failure in rats. *Am J Med Sci* 1994 ;308:331-7
26. Yamagishi H, Akioka K, Itagane H, Tani T, Ohmura T, Yanagi S, Nishikimi T, Yoshiyama M, Toda I, Teragaki M, Takeuchi K, Takeda T. Relationship between insufficient redistribution in exercise thallium-201 myocardial single-photon emission computed tomography and reverse redistribution at rest. *Jpn Circ J* 1995 ;59:23-32
27. Shimada K, Nishikimi T, Kawarabayashi T, Takeuchi K, Takeda T. Effect of prolonged beta-adrenergic blockade induced by atenolol on left ventricular remodeling after acute myocardial infarction in the rat. *Jpn Heart J* 1995 ;36:81-9

28.Omura T, Teragaki M, Takagi M, Tani T, Nishida Y, Yamagishi H, Yanagi S, Nishikimi T, Yoshiyama M, Toda I, Akioka K, Takeuchi K, Takeda T. Myocardial infarct size by serum troponin T and myosin light chain 1 concentration. *Jpn Circ J* 1995 ;59:154-9

29.Nishikimi T, Yamagishi H, Takeuchi K, Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. *Cardiovasc Res* 1995 ;29:856-61

30.Nishikimi T, Tani T, Ohmura T, Yamagishi H, Yanagi S, Yoshiyama M, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T. Angiotensin II type-1 receptor antagonist as well as angiotensin converting enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats. *Jpn Circ J* 1995 ;59:754-61

31.Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Increased plasma levels of adrenomedullin in patients with heart failure. *J Am Coll Cardiol* 1995 ;26:1424-31

32.Nishikimi T, Kawano Y, Saito Y, Matsuoka H. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. *J Cardiovasc Pharmacol* 1996 ;27:275-82

33.Yoshitomi Y, Nishikimi T, Abe H, Yoshiwara F, Suzuki T, Ashizawa A, Nagata S, Kuramochi M, Matsuoka H, Omae T. Comparison of changes in cardiac structure after treatment in secondary hypertension. *Hypertension* 1996 ;27:319-23

34.Yoshihara F, Nishikimi T, Yoshitomi Y, Nakasone I, Abe H, Matsuoka H, Omae T. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. *Am J Hypertens* 1996 ;9:523-8

35.Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. *Hypertension* 1996 ;28:22-30

36. Nishikimi T, Matsuoka H, Ishikawa K, Yoshihara F, Kawano Y, Kitamura K, Saito Y, Kangawa K, Matsuo H, Omae T. Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. *Hypertens Res* 1996 ;19:97-101
37. Ishimitsu T, Nishikimi T, Matsuoka H, Kangawa K, Kitamura K, Minami J, Matsuo H, Eto T. Behaviour of adrenomedullin during acute and chronic salt loading in normotensive and hypertensive subjects. *Clin Sci* 1996 ;91:293-8
38. Yoshitomi Y, Nishikimi T, Abe H, Nagata S, Kuramochi M, Matsuoka H, Omae T. Left ventricular systolic and diastolic function and mass before and after antihypertensive treatment in patients with essential hypertension. *Hypertens Res* 1997 ;20:23-8
39. Nishikimi T, Morimoto A, Ishikawa K, Saito Y, Kangawa K, Matsuo H, Kitamura K, Takishita S, Matsuoka H. Different secretion patterns of adrenomedullin, brain natriuretic peptide, and atrial natriuretic peptide during exercise in hypertensive and normotensive subjects. *Clin Exp Hypertens* 1997 ;19:503-18
40. Morimoto A, Nishikimi T, Takaki H, Okano Y, Matsuoka H, Takishita S, Kitamura K, Miyata A, Kangawa K, Matsuo H. Effect of exercise on plasma adrenomedullin and natriuretic peptide levels in myocardial infarction. *Clin Exp Pharmacol Physiol* 1997 ;24:315-20
41. Yoshibayashi M, Kamiya T, Kitamura K, Saito Y, Kangawa K, Nishikimi T, Matsuoka H, Eto T, Matsuo H. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. *Am J Cardiol* 1997 ;79:1556-8
42. Sumimoto T, Nishikimi T, Mukai M, Matsuzaki K, Murakami E, Takishita S, Miyata A, Matsuo H, Kangawa K. Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension. *Hypertension* 1997 ;30:741-5
43. Kawano Y, Matsuoka H, Nishikimi T, Takishita S, Omae T. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes. *Am J Hypertens* 1997 ;10:1240-4

44. Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, Matsuo H, Kangawa K. Cardiac production and secretion of adrenomedullin are increased in heart failure. *Hypertension* 1997 ;30:1369-75
45. Nishikimi T, Nagata S, Sasaki T, Tomimoto S, Matsuoka H, Takishita S, Kitamura K, Miyata A, Matsuo H, Kangawa K. Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis. *Heart* 1997 ;78:390-5
46. Nishikimi T. Adrenomedullin in cardiovascular disease. *Adv Pharmacol* 1998;42:599-603
47. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, Kangawa K. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. *J Am Coll Cardiol* 1998 ;31:202-8
48. Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, Daikoku S, Matsumoto T, Miyazaki S, Matsuoka H, Takishita S, Kangawa K, Matsuo H, Nonogi H. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. *Am Heart J* 1998 ;135:21-8
49. Miyao Y, Nishikimi T, Goto Y, Miyazaki S, Daikoku S, Morii I, Matsumoto T, Takishita S, Miyata A, Matsuo H, Kangawa K, Nonogi H. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. *Heart* 1998 ;79:39-44
50. Yoshitomi Y, Nishikimi T, Kojima S, Kuramochi M, Takishita S, Matsuoka H, Miyata A, Matsuo H, Kangawa K. Plasma levels of adrenomedullin in patients with acute myocardial infarction. *Clin Sci*. 1998 ;94:135-9
51. Ishimitsu T, Minami J, Nishikimi T, Kawano Y, Takishita S, Kangawa K, Matsuo H, Matsuoka H. Responses of natriuretic peptides to acute and chronic salt loading in normotensive and hypertensive subjects. *Hypertens Res* 1998 ;21:15-22
52. Yoshitomi Y, Nishikimi T, Kojima S, Kuramochi M, Takishita S, Kangawa K, Matsuo H. Plasma natriuretic peptides as indicators of left ventricular remodeling after myocardial infarction. *Int J*

Cardiol 1998 ;64:153-60

53.Nishikimi T, Hayashi Y, Iribu G, Takishita S, Kosakai Y, Minamino N, Miyata A, Matsuo H, Kuro M, Kangawa K Increased plasma adrenomedullin concentrations during cardiac surgery. Clin Sci 1998 ;94:585-90

54.Yoshihara F, Nishikimi T, Kosakai Y, Isobe F, Matsuoka H, Takishita S, Kawashima Y, Saito Y, Matsuo H, Kangawa K Atrial natriuretic peptide secretion and body fluid balance after bilateral atrial appendectomy by the maze procedure. J Thorac Cardiovasc Surg 1998 ;116:213-9

55.Nagaya N, Nishikimi T, Uematsu M, Kyotani S, Satoh T, Nakanishi N, Matsuo H, Kangawa K Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998 ;136:297-301

56.Nishikimi T, Horio T, Yoshihara F, Nagaya N, Matsuo H, Kangawa K Effect of adrenomedullin on cAMP and cGMP levels in rat cardiac myocytes and nonmyocytes. Eur J Pharmacol 1998 ;353:337-44

57.Kario K, Nishikimi T, Yoshihara F, Takishita S, Yamaoka R, Matsuo T, Matsuo H, Mitsuhashi T, Shimada K, Kangawa K Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24 h blood pressure. J Hypertens 1998 ;16:1253-9

58.Yoshihara F, Nishikimi T, Horio T, Yutani C, Takishita S, Matsuo H, Ohe T, Kangawa K Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. Eur J Pharmacol 1998 ;14:355:33-9

59.Horio T, Nishikimi T, Yoshihara F, Nagaya N, Matsuo H, Takishita S, Kangawa K Production and secretion of adrenomedullin in cultured rat cardiac myocytes and nonmyocytes: stimulation by interleukin-1beta and tumor necrosis factor-alpha. Endocrinology 1998 ;139:4576-80

60.Matsuo K, Nishikimi T, Yutani C, Kurita T, Shimizu W, Taguchi A, Suyama K, Aihara N, Kamakura S, Kangawa K, Takamiya M, Shimomura K Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation 1998 ;98:2433-40

61. Kakishita M, Nishikimi T, Okano Y, Satoh T, Kyotani S, Nagaya N, Fukushima K, Nakanishi N, Takishita S, Miyata A, Kangawa K, Matsuo H, Kunieda T Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. *Clin Sci* 1999;96:33-39
62. Nagaya N, Goto Y, Nishikimi T, Uematsu M, Miyao Y, Kobayashi Y, Miyazaki S, Hamada S, Kuribayashi S, Takamiya M, Matsuo H, Kangawa K, Nonogi H Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction. *Clin Sci* 1999 ;96:129-36
63. Nagaya N, Nishikimi T, Horio T, Yoshihara F, Kanazawa A, Matsuo H, Kangawa K Cardiovascular and renal effects of adrenomedullin in rats with heart failure. *Am J Physiol* 1999 ;276:R213-8
64. Nagaya N, Nishikimi T, Uematsu M, Yoshitomi Y, Miyao Y, Miyazaki S, Goto Y, Kojima S, Kuramochi M, Matsuo H, Kangawa K, Nonogi H Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. *Heart* 1999 ;81:483-7
65. Morimoto A, Nishikimi T, Yoshihara F, Horio T, Nagaya N, Matsuo H, Dohi K, Kangawa K Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. *Hypertension* 1999 ;33:1146-52
66. Yoshibayashi M, Kamiya T, Nishikimi T, Saito Y, Matsuo H, Kangawa K Elevated plasma levels of adrenomedullin in congenital cyanotic heart disease. *Clin Sci* 1999;96:543-7
67. Sasaki T, Noguchi T, Komamura K, Nishikimi T, Yoshikawa H, Miyatake K Differential roles of endothelin-1 in the development of secondary pulmonary hypertension in patients with left heart failure with or without acute exacerbation. *J Card Fail* 1999 ;5:38-45
68. Sasaki T, Kubo T, Komamura K, Nishikimi T Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. *J Cardiol* 1999 ;33:317-25
69. Minegishi T, Nakamura M, Abe K, Tano M, Andoh A, Yoshida M, Takagi T, Nishikimi T, Kojima M, Kangawa K Adrenomedullin and atrial natriuretic peptide concentrations in normal pregnancy

and pre-eclampsia. *Mol Hum Reprod* 1999 ;5:767-70

70. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts. *Eur J Pharmacol* 1999 ;382:1-9

71. Ishimitsu T, Minami J, Nishikimi T, Yoshida K, Tsukada H, Kangawa K, Matsuoka H. Changes in plasma adrenomedullin in physiological and pathological conditions in human subjects. *J Cardiovasc Pharmacol* 1999;34(Suppl.4): S47-S51

72. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. *Hypertension* 2000;35:19-24

73. Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. *Circulation* 2000 ;101:498-503

74. Yoshihara F, Nishikimi T, Horio T, Yutani C, Nagaya N, Matsuo H, Ohe T, Kangawa K Ventricular adrenomedullin concentration is a sensitive biochemical marker for volume and pressure overload in rats. *Am J Physiol Heart Circ Physiol* 2000 ;278:H633-H642

75. Hosoya K, Takeda K, Nishikimi T, Ishimitsu T, Matsuoka H Force-length relationship in dogs as a measure of protective effect of imidapril on regional myocardial ischemia and reperfusion injury. *Eur J Pharmacol* 2000 ;390:157-166

76. Yoshihara F, Nishikimi T, Sasako Y, Kobayashi J, Kosakai Y, Hattori R, Horio T, Kitamura S, Matsuo H, Ohe T, Kangawa K Preservation of the right atrial appendage improves reduced plasma atrial natriuretic peptide levels after the maze procedure. *J Thorac Cardiovasc Surg* 2000 ;119:790-794

77. Nagaya N, Nishikimi T, Yoshihara F, Horio T, Morimoto A, Kangawa K Cardiac adrenomedullin gene expression and peptide accumulation after acute myocardial infarction in rats. *Am J Physiol Regul Integr Comp Physiol* 2000 ;278:R1019-R1026

78. Oya H, Nagaya N, Furuichi S, Nishikimi T, Ueno K, Nakanishi N, Yamagishi M, Kangawa K, Miyatake K. Comparison of intravenous adrenomedullin with atrial natriuretic peptide in patients with congestive heart failure. *Am J Cardiol.* 2000 ;86:94-98.
79. Hamanaka I, Saito Y, Nishikimi T, Magaribuchi T, Kamitani S, Kuwahara K, Ishikawa M, Miyamoto Y, Harada M, Ogawa E, Kajiyama N, Takahashi N, Izumi T, Shirakami G, Mori K, Inobe Y, Kishimoto I, Masuda I, Fukuda K, Nakao K. Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. *Am J Physiol Heart Circ Physiol.* 2000 ;279:H388-H396
80. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation* 2000 22;102:865-870
81. Nishikimi T, Matsuoka H, Shimada K, Matsuo H, Kangawa K. Production and clearance sites of two molecular forms of adrenomedullin in human plasma. *Am J Hypertens.* 2000 ;13:1032-4.
82. Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, Miyatake K, Kaneda Y, Tanabe T. Gene Transfer of Human Prostacyclin Synthase Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats. *Circulation.* 2000 ;102:2005-2010.
83. Minami J, Nishikimi T, Ishimitsu T, Makino Y, Kawano Y, Takishita S, Kangawa K, Matsuoka H. Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides levels in obese patients with essential hypertension *J Cardiovasc Pharmacol* 36 (supple.2) S83-86, 2000
84. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Oya H, Kyotani S, Sakamaki F, Ueno K, Nakanishi N, Miyatake K, Kangawa K. Hemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. *Heart* 2000;84:653-658
85. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. *Am J Physiol Heart Circ Physiol.* 2000 ;279:H3031-H3039.

86. Nishikimi T, Nagata S, Sasaki T, Yoshihara F, Nagaya N, Horio T, Matsuo H, Matsuoka H, Kangawa K. The active molecular form of plasma adrenomedullin is extracted in the pulmonary circulation in patients with mitral stenosis: possible role of adrenomedullin in pulmonary hypertension. *Clin Sci.* 2001 ;100:61-66.
87. Asakawa H, Nishikimi T, Suzuki T, Hara S, Tsubokou Y, Yagi H, Yabe A, Tsuchiya N, Horinaka S, Kangawa K, Matsuoka H. Elevation of two molecular forms of adrenomedullin in plasma and urine in patients with acute myocardial infarction treated with early coronary angioplasty. *Clin Sci.* 2001 ;100:117-126.
88. Yoshihara F, Nishikimi T, Okano I, Horio T, Matsuo H, Takishita S, Ohe T, Kangawa K. Alterations of intrarenal adrenomedullin and its receptor system in heart failure rats. *Hypertension.* 2001;37:216-222
89. Nishikimi T, Horio T, Kohmoto Y, Yoshihara F, Nagaya N, Inenaga T, Saito M, Teranishi M, Nakamura M, Ohru M, Kawano Y, Matsuo H, Ishimitsu T, Takishita S, Matsuoka H, Kangawa K. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. *J Hypertens* 2001 ;19:765-73
- (90). Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. [Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension]. *J Cardiol.* 2001 ;37:110-1
90. Nishikimi T, Futo Y, Tamano K, Takahashi M, Suzuki T, Minami J, Honda T, Uetake S, Asakawa H, Kobayashi N, Horinaka S, Ishimitsu T, Matsuoka H. Plasma Brain Natriuretic Peptide Levels in Chronic Hemodialysis Patients: Influence of Coronary Artery Disease. *Am J Kidney Dis* 2001 37: 1201-1208.
91. Kobayashi N, Nishikimi T, Horinaka S, Ishimitsu T, Matsuoka H. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats. *Atherosclerosis.* 2001 ;156:255-65.
92. Nishida K, Watanabe K, Echigo S, Mayumi M, Nishikimi T. Increased plasma adrenomedullin levels in Kawasaki disease with coronary artery involvement *Am J Med* 2001, 111:165-166

93. Nishikimi T, Minami J, Tamano K, Takahashi M, Numabe A, Futoo Y, Honda T, Kobayashi M, Uetake S, Mori Y, Takada M, Machiyama A, Saito T, Matsuoka H. Left ventricular mass relates to average systolic blood pressure, but not loss of circadian blood pressure in stable hemodialysis patients: an ambulatory 48-hour blood pressure study. *Hyp Res* 2001;24:507-514 -27
94. Nishikimi T, Yoshihara F, Kanazawa A, Okano I, Horio T, Nagaya N, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Role of increased circulating and renal adrenomedullin in rats with malignant hypertension. *Am J Physiol Regul Integr Comp Physiol.* 2001;281:R2079-87.
95. Nishikimi T, Minami J, Yasu T, Suzuki T, Kangawa K, Matsuoka K Two molecular forms of plasma adrenomedullin during tilt test in normal healthy subjects. *Peptides* 2001; 22: 1867-1872
96. Yoshihara F, Nishikimi T, Sasako Y, Hino J, Kobatashi J, Hattori R, Minatoya K, Bando K, Kosakai Y, Horio T, Suga S, Takishita S, Matsuoka H, Ikeda Y, Yutani C, Kitamura S, Matsuo H, Ohe T, Kangawa K. Plasma arial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial Ffibrillation. -Plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure - *J Am Coll Cardiol* 2002 ;39:288-294
97. Yoshihara F, Horio T, Nishikimi T, Matsuo H, Kangawa K. Possible involvement of oxidative stress in hypoxia-induced adrenomedullin secretion in cultured rat cardiomyocytes. *Eur J Pharmacol.* 2002;436:1-6.
98. Minami J, Yoshii M, Todoroki M, Nishikimi T, Ishimitsu T, Fukunaga T, Matsuoka H Effects of alcohol restriction on ambulatory blood pressure, heart rate, and heart rate variability in Japanese men *Am J Hypertens* 2002;15:125-129
99. Nishikimi T, Shibasaki I, Iida H, Asakawa H, Matsushita Y, Mori H, Mochizuki Y, Okamura Y, Horinaka S, Kangawa K, Shimada K, Matsuoka H. Molecular forms of adrenomedullin in pericardial fluid and plasma in patients with ischaemic heart disease. *Clin Sci.* 2002 ;102:669-677.
100. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, Yoshihara F, Kangawa K, Matsuoka H. Renoprotective effect of chronic adrenomedullin Infusion in Dahl salt-sensitive rats.

Hypertension. 2002 ;39:1077-1082

101. Mori Y, Nishikimi T, Kobayashi N, Ono H, Kangawa K, Matsuoka H. Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. *Hypertension*. 2002 ;40:107-13.

102. Minami J, Todoroki M, Yoshii M, Mita S, Nishikimi T, Ishimitsu T, Matsuoka H. Effects of smoking cessation or alcohol restriction on metabolic and fibrinolytic variables in Japanese men. *Clin Sci*. 2002 ;103:117-22.

103. Nishikimi T, Tadokoro K, Wang X, Mori Y, Asakawa H, Akimoto K, Yoshihara F, Horio T, Minamino N, Matsuoka H. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. *Eur J Pharmacol*. 2002 ;453:175-81.

104. Iwashima Y, Horio T, Takami Y, Inenaga T, Nishikimi T, Takishita S, Kawano Y. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. *Am J Kidney Dis*. 2002 ;40:974-982.

105. Sano H, Miyata A, Horio T, Nishikimi T, Matsuo H, Kangawa K. The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor. *Regul Pept*. 2002 ;109:107-13.

106. Minami J, Nishikimi T, Todoroki M, Kashiwakura C, Yagi H, Ono H, Horinaka S, Ishimitsu T, Kangawa K, Matsuoka H. Source of plasma adrenomedullin in patients with pheochromocytoma. *Am J Hypertens*. 2002 ;15:994-7

107. Kobayashi N, Horinaka S, Mita S, Yoshida K, Honda T, Kobayashi T, Hara K, Nishikimi T, Matsuoka H. Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in failing hearts of salt-sensitive hypertensive rats. *J Hypertens*. 2002 ;20:2475-85.

108. Makino I, Makino Y, Yoshihara F, Nishikimi T, Kawarabayashi T, Kangawa K, Shibata K. Decreased mature adrenomedullin levels in feto-maternal tissues of pregnant women with histologic chorioamnionitis. *Biochem Biophys Res Commun*. 2003 ;301:437-42.

109. Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective Effect of Adrenomedullin in Heart Failure. *Hyp Res* 2003;26: S121-S127
110. Nagaya N, Miyatake K, Kyotani S, Nishikimi T, Nakanishi N, Kangawa K. Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. *Hyp Res* 2003;26: S141-S146
111. Nishikimi T, Tadokoto K, Mori Y, Wang X, Akimoto K, Yoshihara F, Minamino N, Kangawa K, Matsuoka H. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats *Hypertension* 2003 41: 512-518
112. Tadokoro K, Nishikimi T, Mori Y, Wang X, Akimoto K, Matsuoka H. Altered gene expression of adrenomedullin and its receptor system and molecular forms of tissue adrenomedullin in left ventricular hypertrophy induced by malignant hypertension. *Regul Pept.* 2003 ;112:71-8.
113. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y, Kangawa K. Gene expression, secretion, and autocrine action of C-type natriuretic Peptide in cultured adult rat cardiac fibroblasts. *Endocrinology.* 2003 ;144:2279-84.
114. Wang X, Nishikimi T, Akimoto K, Tadokoro K, Mori Y, Minamino N. Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic. *J Hypertens* 2003; 21:1171-1181
115. Alexander MR, Knowles JW, Nishikimi T, Maeda N. Increased atherosclerosis and smooth muscle cell hypertrophy in natriuretic Peptide receptor  $\alpha^{-/-}$ -apolipoprotein  $e^{-/-}$  mice. *Arterioscler Thromb Vasc Biol.* 2003;23:1077-1082.
116. Watanabe K, Nishikimi T, Takamuro M, Yasuda K, Ishikawa Y, Tanabe S, Yamada O, Nagaya N, Matsuoka H, Kangawa K, Echigo S. Two Molecular Forms of Adrenomedullin in Congenital Heart Disease. *Pediatr Cardiol.* 2003;24:559-565
117. Takahashi M, Nishikimi T, Tamano K, Hara S, Kobayashi T, Honda T, Uetake S, Mitobe R, Matsuoka H. Multiple left ventricular diverticula detected by second harmonic imaging.

Circ J. 2003 ;67:972-4.

118. Nishikimi T, Yoshihara F, Horinaka S, Kobayashi N, Mori Y, Tadokoro K, Akimoto K, Minamino N, Kangawa K, Matsuoka H. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. *Hypertension*. 2003 ;42:1034-41.

118'. Author's Reply-Diagnostic Process of Left Ventricular Diverticulum - Takahashi M, Nishikimi T, Matsuoka H. *Circ J*. 68:272-273

119. Nishikimi T, Mori Y, Ishimura K, Tadokoro K, Yagi H, Yabe A, Horinaka S, Matsuoka H. Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. *Am J Med*. 2004 ;116:517-523.

120. Nishikimi T, Matsuoka H. Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure. *Circulation*. 2004 ;109:e325-6

121. Nishikimi T, Matsuoka H. Are plasma levels of atrial natriuretic peptide, N-terminal ProANP, and brain natriuretic peptide affected by the presence of coronary artery disease? *Circulation*. 2004 ;109:e331

122. Nishikimi T, Matsuoka H. Plasma brain natriuretic peptide levels indicate the distance from decompensated heart failure. *Circulation*. 2004 ;109:e329-30

123. Nishikimi T, Asakawa H, Tadokoro K, Mori Y, Iida H, Shibasaki I, Matsushita Y, Mori H, Mochizuki Y, Kangawa K, Matsuoka H. Different secretion patterns of two molecular forms of cardiac adrenomedullin in pressure- and volume-overloaded human heart failure. *J Cardiac Failure*. 2004;10: 321-327

124. Minami J, Nishikimi T, Matsuoka H. Plasma brain natriuretic peptide and N-terminal proatrial natriuretic peptide levels in obese patients: a cause or result of hypertension? *Circulation*. 2004;110:e76

125. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, Shimokawa H, Ono H,

- Matsuoka H. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. *J Hypertens*. 2004;22:1787-96.
126. Nishikimi T, Wang X, Akimoto K, Tadokoro K, Mori Y, Ishikawa Y, Ishimura K, Yoshihara F, Minamino N, Kangawa K, Matsuoka H. Alteration of renal adrenomedullin and its receptor system in the severely hypertensive rat: effect of diuretic. *Regul Pept*. 2005 ;124:89-98.
127. Nishikimi T, Matsuoka H. Letters Regarding Article by Bibbons-Domingo et al, "B-Type Natriuretic Peptide and Ischemia in Patients With Stable Coronary Disease: Data From the Heart and Soul Study" *Circulation*. 2005;111:e15.
128. Yoshihara F, Nishikimi T, Okano I, Hino J, Horio T, Tokudome T, Suga SI, Matsuoka H, Kangawa K, Kawano Y. Upregulation of intracardiac adrenomedullin and its receptor system in rats with volume overload-induced cardiac hypertrophy. *Regul Pept*. 2005;127:239-244.
129. Yoshihara F, Suga SI, Yasui N, Horio T, Tokudome T, Nishikimi T, Kawano Y, Kangawa K. Chronic administration of adrenomedullin attenuates the hypertension and increases renal nitric oxide synthase in Dahl salt-sensitive rats. *Regul Pept*. 2005;128:7-13.
130. Nishikimi T, Tadokoro K, Akimoto K, Mori Y, Ishikawa Y, Ishimura K, Horio T, Kangawa K, Matsuoka H. Response of adrenomedullin system to cytokine stimulation in cardiac fibroblasts - Role of adrenomedullin as an antifibrotic factor- *Cardiovasc Res* 2005;66:94-103
131. Nishikimi T, Hagaman J, Takahashi N, Kim S, Matsuoka H, Smithies O, Maeda N. Increased susceptibility to heart failure in mice lacking natriuretic peptide receptor-A gene *Cardiovasc Res*. 2005;66:104-113
132. Nishikimi T and Matsuoka H. Adrenomedullin in hypertension. *Current Hypertension Review* 2005;1:169-181
133. Yasu T, Nishikimi T, Kobayashi N, Ikeda N, Ueba H, Nakamura T, Funayama H, Kubo N, Kawakami M, Matsuoka H, Kangawa K, Saito M. Up-regulated synthesis of mature-type adrenomedullin in coronary circulation immediately after reperfusion in patients with anterior acute myocardial infarction. *Regul Pept*. 2005 ;129:161-6.

134. Nishikimi T and Matsuoka H. Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure. *Curr Med Chem Cardiovasc Hematol Agents*. 2005;3:231-42.
135. Ishimura K, Nishikimi T, Akimoto K, Ono H, Kangawa K, Matsuoka H. Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats. *J Hypertens*. 2005 ;23:2287-96.
136. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. *Cardiovasc Res*. 2006 ;69:318-28.
137. Hattori Y, Akimoto K, Nishikimi T, Matsuoka H, Kasai K. Activation of AMP-activated protein kinase enhances angiotensin ii-induced proliferation in cardiac fibroblasts. *Hypertension*. 2006 ;47:265-70.
138. Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. *J Pharmacol Sci*. 2006;100:22-28.
139. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. *Hypertension*. 2006;47:1075-83.
140. Nishikimi T. Editorial Comments : Do increased plasma adrenomedullin levels in normotensive subjects precede hypertension? *J Hum Hypertens*. 2006;20:557-9.
141. Nishikimi T, Mori Y, Ishimura K, Ishikawa Y, Koshikawa S, Tadokoro K, Akimoto K, Ono H, Kangawa K, Matsuoka H. Chronic effect of combined vasopeptidase inhibition and adrenomedullin in heart failure in rats. *Am J Hypertension* 2006;19:1039-1048
142. Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular Adiponectin Activates Nuclear Factor- $\kappa$ B and Activating Protein-1 and Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts. *Diabetes*. 2007;56:804-8.

143. Caron K, Hagaman J, Nishikimi T, Kim HS, Smithies O. Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. *Proc Natl Acad Sci U S A.* 2007;104:3420-
144. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, Ono H, Matsuoka H. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. *J Hypertens.* 2007;25:1053-63.
145. Ikeda N, Yasu T, Nishikimi T, Nakamura T, Kubo N, Kawakami M, Momomura S, Saito M. N-terminal pro-atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. *Regul Pept.* 2007;141:154-8.
146. Watanabe K, Nishikimi T, Takamuro M, Yasuda K, Ishikawa Y, Tanabe S, Yamada O, Yagihara T, Suga S, Kangawa K, Matsuoka H, Echigo S. Possible role of adrenomedullin in the regulation of Fontan circulation: mature form of plasma adrenomedullin is extracted in the lung in patients with Fontan procedure. *Regul Pept.* 2007;141:129-34
147. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. *Curr Med Chem.* 2007;14:1689-99.
148. Nishikimi T, Minamino N, Horii K, Matsuoka H. Do Commercially Available Assay Kits for B-Type Natriuretic Peptide Measure Pro-BNP1-108, as Well as BNP1-32? *Hypertension.* 2007;50:e163.
149. Takemura N, Kono K, Tadokoro K, Shinbo G, Ito I, Abe C, Matsuhashi N, Iemura T, Nishikimi T, Horinaka S, Matsuoka H. Right atrial abnormalities in a patient with arrhythmogenic right ventricular cardiomyopathy without ventricular tachycardia. *J Cardiol.* 2008;51:205-9.
150. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. *J Hypertens.* 2008;26:1837-48.
151. Iemura-Inaba C, Nishikimi T, Akimoto K, Yoshihara F, Minamino N, Matsuoka H. Role of

adrenomedullin system in lipid metabolism and its signaling mechanism in cultured adipocytes.

*Am J Physiol Regul Integr Comp Physiol.* 2008;295:R1376-84.

152. Nishikimi T, Iemura-Inaba C, Akimoto K, Ishikawa K, Koshikawa S, Matsuoka H. Stimulatory and Inhibitory regulation of lipolysis by the NPR-A/cGMP/PKG and NPR-C/G(i) pathways in rat cultured adipocytes. *Regul Pept.* 2009;153:56-63.

153. Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. *Regul Pept.* 2009;154:45-53

154. Nishikimi T, Karasawa T, Inaba C, Ishimura K, Tadokoro K, Koshikawa S, Yoshihara F, Nagaya N, Sakio H, Kangawa K, Matsuoka H. Effects of Long-Term Intravenous Administration of Adrenomedullin plus Human Atrial Natriuretic Peptide Therapy in Acute Decompensated Heart Failure: a pilot study *Circ J* 2009;73:892-898

155. Nishikimi T, Minamino N, Ikeda M, Takeda Y, Iemura-Inaba C, Ishimura K, Tadokoro K, Shibasaki I, Mochizuki Y, Fukuda H, Horiuchi Y, Oikawa O, Ieiri T, Matsubara M, Matsuoka M. Diversity of Molecular Forms of Plasma Brain Natriuretic Peptide in Heart failure –Different proBNP-108 to BNP-32 Ratios in Atrial and Ventricular Overload – *Heart.* 2010;96:432-9

156. Takeda Y, Nishikimi T, Akimoto K, Matsuoka H, Ishimitsu T. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. *Hypertens Res.* 2010;33:965-73

157. Shibasaki I, Nishikimi T, Mochizuki Y, Yamada Y, Yoshitatsu M, Inoue Y, Kuwata T, Ogawa H, Tsuchiya G, Ishimitsu T, Fukuda H. Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-C in epicardial adipose tissue in coronary artery disease. *Regul Pept.* 2010;165:210-217

158. Hata L, Murakami M, Kuwahara K, Nakagawa Y, Kinoshita H, Usami S, Yasuno S, Fujiwara M, Kuwabara Y, Minami T, Yamada Y, Yamada C, Nakao K, Ueshima K, Nishikimi T, Nakao K.

Zinc-finger protein 90 negatively regulates neuron-restrictive silencer factor-mediated transcriptional repression of fetal cardiac genes. *J Mol Cell Cardiol.* 2011;50:972-81.

159. Maisel AS, Nakao K, Ponikowski P, Peacock WF, Yoshimura M, Suzuki T, Tsutamoto T, Filippatos GS, Saito Y, Seino Y, Minamino N, Hirata Y, Mukoyama M, Nishikimi T, Nagai R. Japanese-Western consensus meeting on biomarkers. *Int Heart J.* 2011;52:253-65.

160. Nishikimi T, Minamino N, Nakao K. Diverse molecular forms of plasma B-type natriuretic peptide in heart failure. *Curr Heart Fail Rep.* 2011;8:140-6.

161. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. *J Cardiol.* 2011;57:131-40.

162. Nishikimi T, Nakao K, Kangawa K. Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication. *Current Hypertension Review* 2011;7:273-283

163. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, Fukuda H, Kinoshita H, Nakagawa Y, Kuwahara K, Nakao K. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. *Heart.* 2012 Jan;98:152-61.

164. Kuwahara K, Nishikimi T, Nakao K. Transcriptional regulation of the fetal cardiac gene program. *J Pharmacol Sci.* 2012;119:198-203.

165. Nishikimi T. Do plasma levels of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) increase in diastolic dysfunction as well as in systolic dysfunction? *Circ J.* 2012;76:2540-1.

166. Minami T, Kuwahara K, Nakagawa Y, Takaoka M, Kinoshita H, Nakao K, Kuwabara Y, Yamada Y, Yamada C, Shibata J, Usami S, Yasuno S, Nishikimi T, Ueshima K, Sata M, Nakano H, Seno T, Kawahito Y, Sobue K, Kimura A, Nagai R, Nakao K. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. *EMBO J.* 2012;31:4428-40.

167. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Minamino N, Nakao K. Complexity of molecular forms of B-type natriuretic peptide in heart failure. *Heart*. 2013;99:677-9.
168. Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, Nagata K, Nakagawa Y, Kinoshita H, Yamada C, Nakao K, Minami T, Kuwabara Y, Kuwahara K, Masuda I, Kangawa K, Minamino N, Nakao K. Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure. *PLoS One*. 2013;8:e53233.
169. Kuwabara Y, Kuwahara K, Takano M, Kinoshita H, Arai Y, Yasuno S, Nakagawa Y, Igata S, Usami S, Minami T, Yamada Y, Nakao K, Yamada C, Shibata J, Nishikimi T, Ueshima K, Nakao K. Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts. *J Am Heart Assoc*. 2013;2:e000150.
170. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Nakao K. Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application. *Curr Protein Pept Sci*. 2013;14:256-67.
171. Yasuno S, Kuwahara K, Kinoshita H, Yamada C, Nakagawa Y, Usami S, Kuwabara Y, Ueshima K, Harada M, Nishikimi T, Nakao K. Angiotensin II type 1a receptor signalling directly contributes to the increased arrhythmogenicity in cardiac hypertrophy. *Br J Pharmacol*. 2013;170:1384-95.
172. Wetzel-Strong SE, Li M, Klein KR, Nishikimi T, Caron KM. Epicardial-derived adrenomedullin drives cardiac hyperplasia during embryogenesis. *Dev Dyn*. 2014 ;243:243-56.
173. Nakagawa Y, Nishikimi T, Kuwahara K, Yasuno S, Kinoshita H, Kuwabara Y, Nakao K, Minami T, Yamada C, Ueshima K, Ikeda Y, Okamoto H, Horii K, Nagata K, Kangawa K, Minamino N, Nakao K. The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-Terminal proBNP in end-stage renal disease patients on dialysis. *PLoS One*. 2014 25;9:e92314.
174. Yamada Y, Kinoshita H, Kuwahara K, Nakagawa Y, Kuwabara Y, Minami T, Yamada C, Shibata J, Nakao K, Cho K, Arai Y, Yasuno S, Nishikimi T, Ueshima K, Kamakura S, Nishida M, Kiyonaka S, Mori Y, Kimura T, Kangawa K, Nakao K. Inhibition of N-type Ca<sup>2+</sup> channels

ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure. *Cardiovasc Res.* 2014;104:183-93.

175. Tomiyama H, Nishikimi T, Matsumoto C, Kimura K, Odaira M, Shiina K, Yamashina A. Longitudinal Changes in Late Systolic Cardiac Load and Serum NT-proBNP Levels in Healthy Middle-Aged Japanese Men. *Am J Hypertens.* 2015;28:452-8.

176. Nishikimi T, Nakagawa Y, Minamino N, Ikeda M, Tabei K, Fujishima A, Takayama K, Akimoto K, Yamada C, Nakao K, Minami T, Kuwabara Y, Kinoshita H, Tsutamoto T, Ishimitsu T, Kangawa K, Kuwahara K, Nakao K. Pro-B-type natriuretic peptide is cleaved intracellularly: impact of distance between O-glycosylation and cleavage sites. *Am J Physiol Regul Integr Comp Physiol.* 309:R639-49, 2015

177. Yamada C, Kuwahara K, Yamazaki M, Nakagawa Y, Nishikimi T, Kinoshita H, Kuwabara Y, Minami T, Yamada Y, Shibata J, Nakao K, Cho K, Arai Y, Honjo H, Kamiya K, Nakao K, Kimura T. The renin-angiotensin system promotes arrhythmogenic substrates and lethal arrhythmias in mice with non-ischaemic cardiomyopathy. *Cardiovasc Res.* 109:162-73, 2016

178. Nakao K, Kuwahara K, Nishikimi T, Nakagawa Y, Kinoshita H, Minami T, Kuwabara Y, Yamada C, Yamada Y, Tokudome T, Nagai-Okatani C, Minamino N, Nakao YM, Yasuno S, Ueshima K, Sone M, Kimura T, Kangawa K, Nakao K. Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity. *Hypertension.* 69:286-296, 2017

179. Nakagawa Y, Nishikimi T, Kuwahara K, Fujishima A, Oka S, Tsutamoto T, Kinoshita H, Nakao K, Cho K, Inazumi H, Okamoto H, Nishida M, Kato T, Fukushima H, Yamashita JK, Wijnen WJ, Creemers EE, Kangawa K, Minamino N, Nakao K, Kimura T. MiR30-GALNT1/2 Axis-Mediated Glycosylation Contributes to the Increased Secretion of Inactive Human Prohormone for Brain Natriuretic Peptide (proBNP) From Failing Hearts. *J Am Heart Assoc.* 6. pii: e003601, 2017

180. Kuwahara K, Nakagawa Y, Nishikimi T. Cutting Edge of Brain Natriuretic Peptide (BNP) Research - The Diversity of BNP Immunoreactivity and Its Clinical Relevance. *Circ J.* 2018;82:2455-2461.

181. Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. *Peptides*. 2019 ;111:18-25.
182. Takahama H, Takashio S, Nishikimi T, Hayashi T, Nagai-Okatani C, Nakagawa Y, Amaki M, Ohara T, Hasegawa T, Sugano Y, Kanzaki H, Yasuda S, Kangawa K, Minamino N, Anzai T. Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: A novel compensatory mechanism for acute heart failure. *Int J Cardiol*. 2018;258:165-171.
183. Nishikimi T, Nakagawa Y. Adrenomedullin as a Biomarker of Heart Failure. *Heart Fail Clin*. 2018;14:49-55.
184. Nakagawa Y, Nishikimi T, Sakai H, Ohno S, Kinoshita H, Inazumi H, Moriuchi K, Kuwahara K, Horie M, Kimura T. Macro-pro-B-type natriuretic peptide (proBNP) and hidden macro-N-terminal proBNP: Case report. *Clin Biochem*. 2018;52:148-152.
185. Masuta K, Funatsuki K, Inoue Y, Masuda I, Nishikimi T, Nakagawa Y, Horii K, Nishi H, Igarashi M1, Ota N. A Mixture of Glycosylated proBNP and BNP-32 Is a Suitable Calibrator for BNP Immunoassays. *Open Journal of Clinical Diagnostics*, 2019, 9, 51-63
186. Takahama H, Nishikimi T, Takashio S, Hayashi T, Nagai-Okatani C, Asada T, Fujiwara A, Nakagawa Y, Amano M, Hamatani Y, Okada A, Amaki M, Hasegawa T, Kanzaki H, Nishimura K5, Yasuda S, Kangawa K, Anzai T, Minamino N, Izumi C. Change in the NT-proBNP/Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure: A Novel Predictor Candidate for Cardiorenal Syndrome. *J Am Heart Assoc*. 2019;8:e011468.
187. Takashio S, Takahama H, Nishikimi T, Hayashi T, Nagai-Okatani C, Matsuo A, Nakagawa Y, Amano M, Hamatani Y, Okada A, Amaki M, Hasegawa T, Kanzaki H, Yasuda S, Kangawa K, Anzai T, Minamino N, Izumi C. Superiority of proatrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: comparison with B-type natriuretic peptide and other natriuretic peptide forms. *Open Heart*. 2019;6:e001072.

188. Nishikimi T, Nakagawa Y. Does impaired processing of pro-B-type (or brain) natriuretic peptide cause decreased plasma BNP levels in obese heart failure patients? *Ann Transl Med.* 2019;7(Suppl 6):S221.
189. Kishima M, Wakabayashi H, Kanazawa H, Itoda M, Nishikimi T. Glottal closure surgery for dysphagia associated with cerebral hemorrhage, tongue defect, and sarcopenia: a case report *Progress in Rehabilitation Medicine* 2018; 3: 20180020
190. Horie K, Hossain MS, Kim Y, Ishida A, Kon R, Yamatsu A, Kishima M, Nishikimi T, Kim M. Effects of Banafine®, a fermented green banana-derived acidic glycoconjugate on influenza vaccine antibody titer in elderly patients receiving gastrostomy tube feeding. *J Food Sci.* 2021;86:1410-1417.
191. Tamamura Y, Matsuura M, Shiba S, Nishikimi T. Heart failure assessed based on plasma B-type natriuretic peptide (BNP) levels negatively impacts activity of daily living in patients with hip fracture. *PLoS One.* 2020;15:e0237387.
192. Nishikimi T, Nakagawa Y. Potential pitfalls when interpreting plasma BNP levels in heart failure practice - pathological conditions that may cause erroneous interpretation of measured plasma BNP levels. *J Cardiol.* 2021;78:269-274.
193. Tamamura Y, Matsuura M, Shiba S, Nishikimi T. Effect of heart failure and malnutrition, alone and in combination, on rehabilitation effectiveness in patients with hip fracture. *Clin Nutr ESPEN.* 2021 Aug;44:356-366.
194. Kimura A, Takahama H, Nishikimi T, Takashio S, Hayashi T, Nagai-Okatani C, Nakagawa Y, Yasuda S, Anzai T, Minamino N, Izumi C. Molecular ratio of mature B-type natriuretic peptide in acute heart failure: an indicator for ventricular contractile recovery. *ESC Heart Fail.* 2021;8:5617-5621.
195. Tamamura Y, Yoshikawa H, Matsuura M, Kashio M, Kurai K, Nozaki S, Nishikimi T. Effect of short-duration, limited rehabilitation on maintenance of the activities of daily living in patients with acute phase of COVID-19. *J Phys Ther Sci.* 2022;34:297-305.

196. Inazumi H, Kuwahara K, Nakagawa Y, Kuwabara Y, Numaga-Tomita T, Kashihara T, Nakada T, Kurebayashi N, Oya M, Nonaka M, Sugihara M, Kinoshita H, Moriuchi K, Yanagisawa H, Nishikimi T, Motoki H, Yamada M, Morimoto S, Otsu K, Mortensen RM, Nakao K, Kimura T. NRSF-GNAO1 Pathway Contributes to the Regulation of Cardiac Ca<sup>2+</sup> Homeostasis. *Circ Res.* 2022;130:234-248.
197. Nishikimi T, Kato J. Cardiac Peptides-Current Physiology, Pathophysiology, Biochemistry, Molecular Biology, and Clinical Application. *Biology (Basel).* 2022;11:330.
198. Nishikimi T, Nakagawa Y. B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era? *Biology (Basel).* 2022;11:1034.
199. Shiba S, Masunaga T, Tamamura T, Matsuura M, Nishikimi T. Relationship between the Severity of constipation and exercise status in the Japanese population according to questionnaire Survey. *GastroHep.* Volume 2022:1-6, Article ID 2378353
200. Nakagawa Y, Nishikimi T. CNP, the Third Natriuretic Peptide: Its Biology and Significance to the Cardiovascular System. *Biology (Basel).* 2022;11:986.
201. Tamamura Y, Matsuura M, Shiba S, Nishikimi T. Effect of comorbid heart failure assessed by plasma B-type natriuretic peptide level on the activities of daily living in patients with hospitalization-associated disability after aspiration pneumonia. *Eur Geriatr Med.* 2024;15:67-72.
202. Tamamura Y, Hachiuma C, Matsuura M, Shiba S, Nishikimi T. Relationship between Improvement in Physical Activity and Three Nutritional Assessment Indicators in Patients Admitted to a Convalescent Rehabilitation Ward. *Nutrients.* 2024;16:2531.
203. Nishikimi T, Kinoshita H, Inazumi H, Kanamori T, Yanagisawa H, Moriuchi K, Nakagawa Y. Adrenomedullin in pulmonary hypertension. *Dan Med J.* 2024;71:A07240498.
204. Tamamura Y, Hachiuma C, Matsuura M, Shiba S, Nishikimi T. Frailty and Energy Intake Deficiency Reduce the Efficiency of Activities of Daily Living in Patients with Musculoskeletal Disorders: A Retrospective Cohort Study. *Nutrients.* 2025;17:1334.

205. Goetze JP, Yanagisawa H, Kinoshita H, Burnett J Jr, Nyberg M, Nishikimi T. Perspectives on C-Type Natriuretic Peptide in Cardiometabolic Disease. *J Am Heart Assoc.* 2025;14:e046011.
206. Nishikimi T, Nakagawa Y, Miyamoto S, Kanamori T, Inazumi H, Yanagisawa H, Moriuchi K, Kinoshita H, Tamamura Y, Takahama H, Minamino N, Ono K. Responses of B-type natriuretic peptide (BNP), mature BNP and proBNP to sacubitril/valsartan differs between responders and non-responders. *Open Heart.* 2025;12:e002990.
207. Yanagisawa H, Kuwahara K, Nakagawa Y, Moriuchi K, Kinoshita H, Inazumi H, Kanamori T, Nishikimi T, Oya M, Nakao K, Ueda Y, Nakamura D, Shimizu K, Yoshie K, Tanaka S, Nakajima D, Sakanoue I, Yasoda A, Nakao K, Kimura T, Ono K. Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension. *Nat Commun.* 2026;17:2331.

1. 奥久雄、錦見俊雄、村井佳代子、安田光隆、寺柿政和、小松祐司、木積一憲、吉村隆喜、生野喜康、竹内一秀、田中忠治郎、武田忠直． 左室短軸 3 断面による左室駆出分画算出の試み：日超医論文集、1984、44、53-54
2. 安田光隆、奥久雄、広田一仁、梶野宏美、錦見俊雄、瓦林孝彦、村井佳代子、吉村隆喜、竹内一秀、武田忠直． Ioproterenol 負荷時の高血圧心の心機能：J.Cardiology、1985、15、761-771
3. 寺柿政和、板金広、広田一仁、錦見俊雄、瓦林孝彦、安田光隆、村井佳代子、秋岡要、吉村隆喜、奥久雄、竹内一秀、武田忠直． 術前後の心機能を評価し得た褐色細胞腫の一症例：日超医論文集、1985、46、205-206
4. 村井佳代子、広田一仁、西上宏美、錦見俊雄、瓦林孝彦、寺柿政和、秋岡要、安田光隆、吉村隆喜、奥久雄、竹内一秀、武田忠直． 第 4 音を有する狭心症の拡張能の検討：日超医論文集、1985、46、205-206
5. 錦見俊雄、板金広、広田一仁、瓦林孝彦、村井佳代子、秋岡要、寺柿政和、安田光隆、吉村隆喜、奥久雄、竹内一秀、武田忠直． 心膜中皮腫 2 例の超音波所見：日超医論文集、1985、47、504-505
6. 葭山稔、広田一仁、錦見俊雄、瓦林孝彦、村井佳代子、安田光隆、秋岡要、寺柿政和、奥久雄、竹内一秀、武田忠直． 高齢者バルサルバ洞破裂の一例：日超医論文集、1986、49、711-712
7. 広田一仁、生野喜康、錦見俊雄、瓦林孝彦、村井佳代子、安田光隆、奥久雄、竹内一秀、武田忠直． 因子分析とフーリエ解析による局所壁運動異常診断能の比較：J.Cardiology、1986、16、319-329
8. 錦見俊雄、河野雅和、栗原直嗣、横山広之、井関敏之． 若年健康人の運動に伴う心房性利尿ペプチドの動態と各種ホルモンの関係：厚生省科研費報告書、1986、44-51

9. 武田忠直、竹内一秀、瓦林孝彦、村井佳代子、錦見俊雄、広田一仁、酒井宏純、寺柿政和. BAYe9736(Nimoldipine)錠の単回ならびに連続投与試験：薬理と治療、1987、15、119-130
10. 河野雅和、秋岡要、村川浩一、錦見俊雄、安成憲一、横川晃治、寺柿政和、松浦敏文、栗原直嗣、安田光隆、奥久雄、竹内一秀、武田忠直. Ca拮抗薬と心房性利尿ペプチド：薬理と治療、1987、15(suppl)、187-193
11. 切池信夫、前田泰久、泉屋洋一、西脇新一、片原節、な井弘二、川北幸男、錦見俊雄、竹内一秀、武田忠直. Thioridazine 投与中に Torsades de Pointes を呈した一例：精神医学、1987、29、301-309
12. 錦見俊雄、広田一仁、酒井宏純、葭山稔、村井佳代子、秋岡要、寺柿政和、安田光隆、奥久雄、竹内一秀、武田忠直. 二次元血流映像法により診断された冠動脈瘤の2例：日超医論文集、1987、50、151-152
13. 板金広、岡本泰之、飯田英隆、成子隆彦、酒井宏純、錦見俊雄、よし山稔、村井佳代子、寺柿政和、秋岡要、安田光隆、奥久雄、竹内一秀、武田忠直. 左室右房交通症、大動脈弁閉鎖不全症に感染性心内膜炎を合併しバルサルバ洞穿孔をきたした一例：日超医論文集、1987、51、621-622
14. 武田忠直、錦見俊雄、河野雅和. 運動負荷とANPL：肺と心、1987、34、324-327
15. 秋岡要、河野雅和、錦見俊雄、寺柿政和、安田光隆、奥久雄、竹内一秀、武田忠直. 本態性高血圧患者における運動負荷時の血行動態および血漿心房性Na利尿ペプチド濃度に及ぼすNisoldipineの影響：基礎と臨床、1988、52、1465-1467
16. 安田光隆、奥久雄、錦見俊雄、村井佳代子、秋岡要、寺柿政和、竹内一秀、武田忠直、井上英二、生野善康. 心尖部肥大型心筋症における拡張障害の局在性：J.Cardiology、1988、18、105-112

17. 葭山稔、金勝慶、山岸広之、大村崇、谷知子、柳志郎、錦見俊雄、戸田為久、寺柿政和、秋岡要、竹内一秀、武田忠直. 虚血心筋障害における心筋組織 ACE の役割、心筋の構造と代謝、15、1993、149-153
18. 錦見俊雄、松岡博昭. 最近の循環器新薬の使い方と問題点 高圧薬高脂血漿薬：循環科学、15、1995：340-343
19. 石光俊彦、錦見俊雄、斎藤能彦、北村和雄、松岡博昭、寒川賢治、松尾壽之、尾前照雄. 各種循環器疾患における血漿アドレノメデュリン濃度と他の循環調節ホルモンとの関係. 心臓 27、suppl 2、1995
20. 錦見俊雄. アドレノメデュリンの臨床研究：循環器病研究の進歩、1995、33-39
21. 錦見俊雄、吉原史樹、森本淳詞、石川一彦、吉富雄二、石光俊彦、松岡博昭、尾前照雄、斎藤能彦、寒川賢治、松尾壽之. 本態性高血圧における血漿 ANP、BNP 濃度測定の意義：心臓 28、1996：197-202
22. 錦見俊雄、吉見宏樹. 高血圧性心不全：別冊日本臨床 領域別症候群シリーズ、循環器症候群 I、42・45
23. 吉見宏樹、錦見俊雄. 心不全『急性心不全、慢性心不全；左心不全、右心不全；収縮期不全、拡張期不全；高拍出性心不全、低拍出性心不全』別冊日本臨床 領域別症候群シリーズ、循環器症候群 I、107・109
24. 石光俊彦、錦見俊雄、南順一、河野雄平、松岡博昭、寒川賢治、松尾壽之. 本態性高血圧における急性、慢性の食塩負荷に対する交感神経、内分泌系の反応：心臓 28 巻、suppl 4 .80-84、1996
25. 錦見俊雄. アドレノメデュリンと循環器疾患：現代医療 28、No11：121-124, 1996

26. 石川一彦、錦見俊雄、吉原史樹、石光俊彦、河野雄平、吉見宏樹、瀧下修一、齋藤能彦、寒川賢治、松尾壽之． 降圧療法に伴って著しい血漿 ANP, BNP, Adrenomedullin 値の低下左室肥大の退縮をみた悪性高血圧の一例：Therapeutic Research. Vol.17: No10: 26-28, 1996
27. 錦見俊雄．腎血管性高血圧とは：Medical Technology 臨時増刊 Vol 25, No 5, 429-435、1997
28. 錦見俊雄．心不全における循環ペプチドの病態 - 生理学的意義と心不全治療への応用： 進歩する心臓研究、1997、 巻、8号、68-82
29. 錦見俊雄，寒川賢治．アドレノメデュリン：臨床検査 1997；Vol41: No 7: 826-828
30. 錦見俊雄．肥大心における ANP, BNP の意義：THERAPEUTIC RESEARCH、1997 vol. 18 suppl. 3 Symposium Series No. 599, page7-9
31. 錦見俊雄．心肥大における ANP, BNP の意義：Modern Physician Vol.17、1997、953-957
32. 錦見俊雄．アドレノメデュリンと心不全：Heart View 1997 ;Vol 1: No 8: 56-61
33. 錦見俊雄．アドレノメデュリンの循環器疾患における病態生理的意義：医学の歩み Vol 184, No.1, 1998, 64-69
34. 錦見俊雄．血漿 ANP, BNP 濃度と循環器疾患：Medical Technology ;Vol 26; 1998 No1:105-106
35. 錦見俊雄．21世紀カンファ . 血漿 ANP、BNP と循環器疾患：THERAPEUTIC RESEARCH 1998, Vol 19, no.6, 195-202

36. 錦見俊雄, 寒川賢治. Adrenomedullin と循環調節機構 : Cardiologist Vol3 ; No.5 : 319-325, 1998
37. 錦見俊雄. 私の処方・高血圧緊急症・ : Modern Physician Vol.18、1998、334
38. 錦見俊雄. 心疾患におけるアドレノメデュリンの変化とその意義 : Molecular Medicine, Vol.35、1998、1022-1032
39. 錦見俊雄. 心肥大と ANP, BNP・その臨床的意義 : Progress in Medicine 1998; 10: 28-33
40. 錦見俊雄. アドレノメデュリンの循環器疾患における病態生理的意義の解明と治療への応用 : 研究助成業績報告集、1997、Page 39-42、財団法人循環器病研究振興財団編
41. 中尾一和、斎藤能彦、蔦本尚慶、錦見俊雄. 新しい循環ホルモンの臨床応用ーナトリウム利尿ペプチド系アドレノメデュリンを中心に : 循環科学 Vol.18、1998、1144-1158
42. 錦見俊雄. アドレノメデュリンによる循環調節・高血圧症との関連・ : 医学の歩み Vol.189, 1999, 542-546
43. 堀尾武史、錦見俊雄、吉原史樹、松尾壽之、瀧下修一、寒川賢治. 内因性心房性 Na 利尿ペプチドによる培養心筋細胞肥大抑制作用 : 血圧 Vol. 7、28-32, 1999
44. 錦見俊雄. 心不全におけるアドレノメデュリンの病態生理的意義 : Cardiac Practice Vol.10、1999、79-87
45. 木全心一、宮内卓、錦見俊雄、吉村道博. 座談会『心不全と循環ペプチド』 : Cardiac Practice Vol.10、1999、111-128

46. 錦見 俊雄、堀尾 武史、神本 有美、吉原 史樹、 稲永 隆、 河野 雄平、  
瀧下 修一、 寒川賢治. 高血圧患者の血中および尿中  
Adrenomedullin-Mature(AM-M; 活性型)と AM-Gly (非活性型)の病態生理学  
的意義 THERAPEUTIC RESEARCH Vol.20、1999、34-37
47. 錦見 俊雄. データブック 血栓症の大規模臨床試験 動脈硬化危険因子・  
低用量アスピリンによる心血管予防効果に関する男性医師対象の無作為化  
比較二重盲検試験. 血栓と循環 Vol. 7, 1999, 145-146
48. 錦見俊雄, 寒川賢治. Adrenomedullin と本態性高血圧. 日本臨床 増刊号  
高血圧上巻 Vol. 58 IV.本態性高血圧症-成因と病態生理 アドレノメ  
デュリン 481-486、2000
49. 錦見俊雄、松岡博昭. 日本臨床 増刊号 高血圧上巻 Vol. 58 V.本態性  
高血圧症-臨床 血圧変動因子 ビタミン 690-693、2000
50. 錦見俊雄、松岡博昭. 症例に学ぶ高血圧治療専門医のみるポイント49、  
2000, MEDIACAL VIEW社(片山茂裕、後藤淳朗、島田和幸) 腎血管  
性高血圧の治療指針 page 126-127
51. 錦見俊雄、松岡博昭. 臨床検査診断マニュアル(永井書店)・古澤新平他編  
集 2000 8.心機能 a.心房性ナトリウム利尿ペプチド(ANP)、脳性ナトリ  
ウム利尿ペプチド(BNP)、page 678-681、サイクリックGMP(cGMP) page  
682、 エンドセリン page 683-684
52. 錦見俊雄 軽症高血圧 最新医学社 Vol 4, No. 3, page 12-13 2000
53. 錦見俊雄 高血圧性左室肥大と神経体液性因子 Heart View 2000 ;Vol 4 :  
No 9: page 992-999
54. 鈴木武志、南順一、矢部彰久、轟政勝、植竹修一郎、渡辺滋子、原すおみ、  
坪光雄介、八木博、浅川洋、小野英彦、沼部敦司、堀中繁夫、錦見俊雄、石

光俊彦、本田幹彦、吉田謙一郎、松岡博昭 腹腔鏡下で摘出が可能であった褐色細胞腫の1例 血圧 Vol. 7、83-87、2000

55. 錦見俊雄. Urocortin ホルモンと臨床 Vol.49, 17-22、2001
56. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension J Cardiol. 2001 ;37:110-1. Japanese.
57. 錦見俊雄、松岡博昭 アドレノメデュリンと高血圧症 循環器科 Vol.49、491-497、2001
58. 高橋 正樹, 玉野 宏一, 原 すおみ, 小林 学, 本多 勇晴, 植竹 修一郎, 水戸部 利恵子, 錦見 俊雄, 松岡 博昭多発性の左室憩室の描出に second harmonic imaging が有用であった 1 症例 THE CIRCULATION FRONTIER(1343-2036)5 巻 4 号 Page57-61, 2001
59. 錦見 俊雄. 内蔵内蔵反射 viscerovisceral reflex、大動脈体反射 aortic body reflex、頸動脈小体 carotid body、頸動脈体反射 carotid body reflex、ベインブリッジ反射 bainbridge reflex、
60. 看護医学大辞典. 和田攻、南裕子小峰光博総集編、医学書院(東京)2002
61. 錦見俊雄 高血圧性心肥大と心臓内分泌代謝 血圧 Vol.9, 57-62, 2002
62. 高橋正樹、玉野宏一、原すおみ、小林学、本多勇晴、植竹修一郎、水戸部利恵子、錦見俊雄、松岡博昭 多発性の左室憩室に second harmonic imaging が有用であった1症例 The Circulation Frontier 4 巻、57-61, 2002
63. 錦見俊雄 血漿 BNP 値モニター下での心不全治療 Medical Practice 2002

64. 錦見俊雄 ANP, BNP 測定の意義とその解釈 検査と技術 Vol.30, 561-563, 2002
65. 錦見俊雄 ナトリウム利尿ペプチドを生かした心不全の診断 / 治療の最前線  
・脳性利尿ペプチド(BNP)の心不全診断薬への応用・ 医薬ジャーナル斉藤能彦編 page 44-51, 2003
66. 錦見俊雄 若手研究者による最新海外情報 『生活習慣病に対する分子遺伝学的アプローチ』 血管 Vol.26, 73-75, 2003
67. 錦見俊雄 NSAID と腎機能障害 Medical Practice One Point Advice 2004, Vol 21, page 142
68. 錦見俊雄 アドレノメデュリンと本態性高血圧症 日本臨床 2004;62 Suppl 9:260-3
69. 錦見俊雄 ウロテンシン II と心疾患 日本臨床 2004;62 Suppl 9:722-6
70. 錦見俊雄 : ナトリウム利尿ペプチドを利用した左室肥大の診断と治療効果の判定:高血圧診療のコツと落とし穴. 島田和幸編, 中山書店, pp.26-27
71. 錦見俊雄 (Comment)THERAPEUTIC RESEARCH Vol.25、2004、1102
72. 錦見俊雄 (Comment)THERAPEUTIC RESEARCH Vol.25、2004、1115
73. 錦見俊雄、松岡博昭:8. 心機能 ( a ) 心房性ナトリウム利尿ペプチド ( ANP ) 脳性利尿ペプチド ( BNP ) 臨床検査診断マニュアル、古澤新平、金山正明、橋本博史編、永井書店、pp.678-682, 2004.
74. 錦見俊雄、松岡博昭:8. 心機能 ( d ) サイクリック GMP、臨床検査診断マニュアル、古澤新平、金山正明、橋本博史編、永井書店、pp.683, 2004.

75. 錦見俊雄、松岡博昭:8. 心機能 (e) エンドセリン(ET)、臨床検査診断マニュアル、古澤新平、金山正明、橋本博史編、永井書店、pp.684, 2004.
76. 錦見俊雄 心肥大をともなう高血圧：選択薬剤と降圧目標 EBM ジャーナル 6 巻 2 号 Page204-207, 2005
77. 錦見俊雄 新 BNP と日常診療・心機能異常の早期発見のために・(BNP と生活習慣病) pp.123-138、2005
78. 錦見俊雄、松岡博昭 高血圧による臓器障害のメカニズム Molecular Medicine 臨時増刊号 2005:42;244-250
79. 錦見俊雄 アドレノメデュリンと高血圧、腎疾患 分子血管病 2005:62;51-56
80. 錦見俊雄 JSH2004 ガイドラインの検証 臓器障害を合併する高血圧の治療 メビオ 2005 ;Vol 22 : No 7: page 38-45
81. 錦見俊雄 高血圧性心肥大は降圧薬で退縮可能か、その選択薬剤は？EBM 循環器疾患の治療 2006-2007、三田村秀男、山科明、川名正敏、桑島巖編著、中外医学社、page.442-445、2005.
82. 錦見俊雄、松岡博昭 神経体液性因子を基盤とした心不全治療. 日本臨床生理学誌 Vol 35 : No 4: page 199-205、2005
83. 下条文武、伊藤貞嘉、倉林正彦、代田浩之、錦見俊雄. 座談会 心腎連関における ARB の役割 新薬と臨床 Vol 54 : No 9: page 37-47、2005
84. 小林直彦、錦見俊雄、松岡博昭. Dahl 心不全モデルラット. 日本臨床 Vol 64:S5:303-310
85. 錦見俊雄 心不全を有する高血圧例の降圧薬の使用法 メビオ Vol 23 : No 4: page 51-57、2006

86. 錦見俊雄 第35回日本心脈管作動物質学会学会 血圧 Vol 134 : No 4:  
page 82-83、2006
87. 錦見俊雄、松岡博昭 高血圧性糸球体硬化に対する Rho-kinase 阻害薬の  
腎保護作用とその分子機序 脈管学 46:667-673,2006
88. 錦見俊雄、松岡博昭 循環生理活性物質の血圧調節に関する分子機序と病  
態生理的意義 血管 Vol 29, 37-46, 2006
89. 錦見俊雄 高血圧性糸球体硬化進展における Rho/Rho-kinase 系の役割  
Rho-kinase 阻害薬の糸球体保護効果とその分子機序 - 日本薬理学会誌 Vol  
128, 153-159, 2006
90. 錦見俊雄、松岡博昭. 高脂血症への介入による脳血管障害の再発予防 老  
年医学 Vol 44, 1675-1678, 2006
91. 錦見俊雄. -3- 合併症のある場合、心脈管疾患、これだけは知ってお  
きたい日常診療のポイント 高齢者高血圧、松岡博昭編、54-63、医薬ジャ  
ーナル社、東京、2006
92. 錦見俊雄、 -3- 合併症のある場合、代謝性疾患、これだけは知ってお  
きたい日常診療のポイント 高齢者高血圧、松岡博昭編、70-76、医薬ジャ  
ーナル社、東京、2006
93. 錦見俊雄、松岡博昭. 心不全治療薬併用療法 ARB+ACE 阻害薬 日本臨床  
心不全下巻 65, suppl 5,140-144, 2007
94. 錦見俊雄. Plenary session 3 ISH ハイライト 2007, p127-p130
95. 錦見俊雄. 高血圧診療マニュアル 心筋梗塞、狭心症、心筋症、大動脈瘤、  
高脂血症、高血圧性緊急症

96. 錦見俊雄. 心不全マーカーとしての BNP の意義 日本医事新報 Vol 4324, 122-123, 2007
97. 錦見俊雄. 臓器不全患者の血圧管理. 心不全患者の血圧管理 血圧 14 巻 8 号 Page784-788(2007.08)
98. 錦見 俊雄. 房室弁 atrioventricular (AV) valve、発作性夜間呼吸困難 paroxysmal nocturnal dyspnea;PND 看護医学大辞典. 和田攻、南裕子、小峰光博総集編、医学書院（東京）2007
99. 錦見 俊雄. 最新の心不全薬物療法 栃木病院薬剤師会誌 Vol 72, 19-21, 2007
100. 錦見 俊雄. 心不全マーカーとしての BNP の意義(Q&A) 日本医事新報 4324 号 Page122-123, 2007
101. 南順一、小林直彦、錦見俊雄、松岡博昭. 第 17 回ヨーロッパ高血圧学会（ESH） 血圧 Vol 14 : page 92-93、2007
102. 錦見俊雄 循環器疾患における Adrenomedullin の意義と臨床応用 血圧 Vol 15, 68-73, 2008
103. 錦見俊雄、松岡博昭 プライマリーケア : 43. レビューむくみのメカニズムと最新の治療, 2008
104. 錦見俊雄、松岡博昭 プライマリーケア : 44. 顔面の浮腫 , 2008
105. 錦見俊雄、松岡博昭 プライマリーケア : 45. 下肢の浮腫, 2008
106. 錦見俊雄、松岡博昭 プライマリーケア : 46. 全身の浮腫, 2008

107. 錦見俊雄、松岡博昭 プライマリーケア：47.局所的な浮腫，2008
108. 錦見俊雄、松岡博昭. プライマリーケア：48.手のこわばり，2008
109. 錦見俊雄. 心臓血管系におけるアドレノメデュリンー心不全への臨床応用- 細胞 2008 ; 40,16-19
110. 小林 直彦, 錦見 俊雄, 石光 俊彦, 松岡 博昭. 【実験動物を用いた循環器病研究の進歩】 Dahl ラット心不全モデル. アニテックス (0915-3667)20 巻 3 号 Page21-28(2008.04)
111. 錦見俊雄、心不全と左室肥大. 血圧 15 巻 10 号 Page830-833(2008.10)
112. 小林直彦、錦見俊雄 Dahl 心不全モデルラット 日本臨床 67, 569-577, 2009
113. 錦見俊雄、循環器領域への新しい遺伝子改変マウス作成技術の応用 日本臨床 67, 685-689,2009
114. 錦見俊雄心血管病の診断と治療におけるバイオマーカーの有用性 -BNP- メビオ 26,24-32, 2009
115. 村上礼子、鈴木美津恵、鹿村真理子、錦見俊雄 地域生活を継続している慢性心不全患者のセルフケアー外来患者のセルフケア影響因子に注目してー. 獨協医科大学看護学部紀要 3、1-10、2010
116. 錦見俊雄、桑原宏一郎、中尾一和. 心房性ナトリウム利尿ペプチド (ANP)、脳性ナトリウム利尿ペプチド (BNP) 臨床検査基準値 express2011 p183
117. 錦見俊雄、桑原宏一郎、中尾一和. cAMP 臨床検査基準値 express 2011 p184
118. 桑原宏一郎、錦見俊雄、中尾一和. セロトニン、5-HIAA 臨床検査基

準値 express 2011 p185

119. 錦見俊雄. 分子標的薬と高血圧症、循環器疾患 日本臨床 68, 1911-1916, 2010
120. 錦見俊雄. 心疾患のバイオマーカーとしての BNP の意義—基礎的・臨床的観点から—日本臨床 70:774-84, 2012
121. 錦見俊雄. 降圧薬としてのエンドセリン拮抗薬、PDE 5 阻害薬—治療抵抗性高血圧におけるエンドセリン拮抗薬、PDE 5 阻害薬の可能性—循環器内科 72(5), 515-520, 2012
122. 錦見俊雄. 高血圧管理とバイオマーカー BNP、ANP と高血圧 血圧 19(10),884-889, 2012
123. 桑原 宏一郎, 錦見 俊雄, 中尾 一和. 心血管系の適応と破綻におけるナトリウム利尿ペプチド系の意義. 適応医学(1342-9787)16 巻 2 号 Page8-13(2012.12)
124. 錦見俊雄. ストローマとナトリウム利尿ペプチド—急性心筋梗塞の病態生理学的意義と臨床応用 循環器内科、74(2):174-180, 2013
125. 錦見俊雄. B 型ナトリウム利尿ペプチド (BNP) 分子型の最新知見 - BNP の生化学、分子生物学、臨床的意義を含めて - シーメンスサイエンティフィックインフォメーション 1-11, 2013
126. 錦見俊雄, 南野直人. Na 利尿ペプチドの発見と薬理作用. Fluid Management Renaissance Vol4, No 3, 43-49, 2014
127. 南野直人、錦見俊雄、中川靖章、寒川賢治 BNP の多様な分子型の分別測定による心不全診断法の革新 循環器病研究の進歩 Vol. XXXV No.1(2014.1)p.7-16

128. 錦見俊雄. BNP 検査で潜在性心不全を診るー生活習慣病における BNP 検査の有用性ーシーメンスサイエンティフィックインフォメーション 1-11, 2015
129. 牟田 博行, 村橋 大輔, 上里 圭吾, 新田 勉, 錦見 俊雄. 知っていますか? ドライブシミュレーター 自動車運転再開に向けての方法と紹介. 大阪作業療法ジャーナル (1880-4837)29 巻 2 号 Page92-97(2016.01)
130. 錦見俊雄、松浦道子. 慢性期医療でのリハビリテーション 重症例にもあきらめない、粘り強いリハビリで在宅復帰を目指す わかくさ竜間リハビリテーション病院における取り組み. 日本慢性期医療協会誌 25 巻 4 号 Page57-61(2017.10)
131. 錦見俊雄. 現場からの発言その 101. 循環器内科医から見た超高齢化社会. 老人医療ニュース、141 号、p2, 2017
132. 錦見俊雄, 中川靖章. 心不全診療における BNP 解釈のピットフォール BNP 値を過大評価もしくは過小評価する病態. Heart View 23 巻 8 号 Page736-744(2019.08)
133. 錦見俊雄. 【ナトリウム利尿ペプチドに関する話題】アンジオテンシン受容体・ネプリライシン阻害薬(ARNI)と BNP、NT-proBNP の関係とは? 循環器内科. 2021;89(4):414-419.
134. 杉田智加、錦見俊雄. ポリファーマシーはリハビリテーションの治療効果を減弱するのか? 脳血管疾患患者での検討 リハビリナース 14 巻 5 号 Page502-506(2021.09)
135. 杉田 智加, 錦見 俊雄. ポリファーマシー対策の取り組み ポリファーマシーとリハビリテーションの関係について ポリファーマシー対策も含

めて. 薬事新報. 2021 Mar;3194:7-10

136. 山中 英治, 中尾 昌弘, 清水 あかり, 改發 明子, 渋谷 智美, 平沢 直子, 熊谷 哲也, 錦見 俊雄. 急性期および慢性期入院患者における濃厚流動食サンエット K2 の臨床評価. 新薬と臨牀 70 巻 10 号 Page1275-1285(2021.10)
137. 錦見俊雄. 老人医療こぼれ話. 高齢者のうつ病、認知症雑感. 老人医療 ニュース、147号、p3, 2021
138. 南野直人, 錦見俊雄. ナトリウム利尿ペプチド(まとめ) ヒトを中心とした生理活性ペプチド ハンドブック. p.54-61, 2022
139. 南野直人, 錦見俊雄. 心房性ナトリウム利尿ペプチド. ヒトを中心とした生理活性ペプチド ハンドブック. p.62-64, 2022
140. 南野直人, 錦見俊雄. 心房性ナトリウム利尿ペプチド. ヒトを中心とした生理活性ペプチド ハンドブック p.65-66, 2022
141. 南野直人, 錦見俊雄. 心房性ナトリウム利尿ペプチド. ヒトを中心とした生理活性ペプチド ハンドブック. p.67-68, 2022
142. 南野直人, 錦見俊雄. ウロディラチン. ヒトを中心とした生理活性ペプチド ハンドブック. p.69-70, 2022
143. 南野直人, 錦見俊雄. 脳性ナトリウム利尿ペプチド-32. ヒトを中心とした生理活性ペプチド ハンドブック. p.71-73, 2022
144. 南野直人, 錦見俊雄. 脳性ナトリウム利尿ペプチド. ヒトを中心とした生理活性ペプチド ハンドブック. p.74-75, 2022
145. 玉村悠介, 野崎園子, 朝川弘章, 吉川創, 松浦道子, 錦見俊雄. 回復

期リハビリテーション病棟における入院時オンライン家屋訪問の有用. The Japanese Journal of Rehabilitation Medicine)60 巻 10 号 Page892-901(2023.10).

146. 朝川弘章, 玉村悠介, 牟田博行, 野崎園子, 錦見俊雄. オンライン訪問指導により、回復期リハビリテーション病棟から、早期在宅復帰に繋がった認知機能障害を有する一例. 医療 78 巻 3 号 Page174-177(2024.06)
147. 芝寿実子, 近藤颯, 玉村悠介, 吉川創, 松浦道子, 錦見俊雄. 末梢動脈疾患に伴う重症下肢虚血のために下腿切断となり 義足走行可能に至った一症例 予防を考慮したアプローチ 日本予防理学療法学会雑誌 3 巻 2 号 Page33-38(2024.03)
148. 小川治夫, 古谷真優美, 錦見俊雄, 南野直人. ナトリウム利尿ペプチドとペプチド医薬. 実験医学 43 巻 2 号 Page313-321(2025.02)
149. 芝寿実子, 奥野浩司郎, 玉村悠介, 近藤颯人, 吉川創, 松浦道子, 錦見俊雄. 複数の障害を併発する虚弱下肢切断者における義足歩行獲得までの理学療法の 1 例. 日本フットケア・足病医学会誌 (2435-4775)6 巻 3 号 Page180-185(2025.09)
150. 玉村悠介, 芝寿実子, 松浦道子, 錦見俊雄. 誤嚥性肺炎患者における心不全と低栄養の単独および合併がリハビリテーションアウトカムに与える影響 回復期リハビリテーション病棟における検討. 呼吸理学療法学 4 巻 1 号 Page1-11(2025.03)
151. 錦見俊雄. 老人医療こぼれ話. リハビリテーションはたべることから. 老人医療ニュース, 1597 号, p3, 2026
152. 松浦道子, 樋口由美, 上田哲也, 玄安季, 上月涉, 錦見俊雄. 85 歳以上高齢股関節近位部骨折患者の ADL 改善と身体機能要因の関連性. Jpn J Rehabil Med 2026;63:82-92